Tag: system

London, UK , June 27, 2025 (GLOBE NEWSWIRE) -- WinnerMining, a UK-based digital infrastructure company, has announced the global rollout of its AI-powered cloud mining platform designed to offer a sustainable and user-friendly approach to cryptocurrency mining.


Founded in 2021, WinnerMining now serves over 13 million users across 195 countries. The platform’s latest update introduces an AI intelligent scheduling system, which dynamically allocates computing power to maximize mining efficiency. By eliminating the need for users to manage hardware or handle technical complexities, WinnerMining aims to make digital asset mining more accessible to everyday users and institutional investors alike.


In addition to its AI enhancements, the company has also implemented environmentally sustainable practices, including the integration of solar-powered systems and permanent magnetic smart fans to minimize carbon output. These upgrades reflect the platform’s ongoing commitment to environmental responsibility in the crypto space.


“WinnerMining was built with the mission to simplify cryptocurrency participation while maintaining high standards of security and transparency,” said a company spokesperson. “Our latest innovations reflect our vision for a more inclusive and eco-conscious digital economy.”

Customizable Contracts for Every User
To meet a wide variety of investment goals and comfort levels, winner Mining provides flexible mining contracts designed to suit different user needs. These are categorized into classic, premium, and super tiers, each offering progressively higher earning potential. The platform’s contract options allow users to choose a plan that aligns with their personal strategy and growth expectations. Additional contract details can be found on the official website.

Notable Features Include:

CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA^®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months.